2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

5998 Single-cell multiomics reveals conserved immune homeostasis signatures after allogeneic hematopoietic stem cell transplantation

Jianing Tang, Zhengli Xu2, Xiaojun Huang, MD,PhD3, Huidong Guo4
1 Peking University People’s Hospital, Beijing, China
2 Peking University People’s Hospital, Beijing, China, Peking University People’s Hospital, beijing, China
3 Peking University People’s Hospital, Beijing, China
4 Peking University People’s Hospital, Beijing, China

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for a wide range of malignant and non-malignant hematologic disorders. Following engraftment, donor-derived immune cells must simultaneously maintain protective immunity against pathogens and residual malignant cells while establishing tolerance to recipient tissues. While immune features associated with successful homeostasis have been explored in hematologic malignancies, whether these features are conserved across non-malignant diseases and how donor-derived immune cells clonally evolve post-transplantation remain elusive. Understanding the cellular and molecular basis of this state remains a central challenge in transplantation biology.

To investigate the shared patterns and distinct features of immune reconstitution culminating in immune homeostasis following allo-HSCT across diverse disease backgrounds, we integrated paired donor-recipient single-cell RNA sequencing (scRNA-seq) and single-cell T-cell receptor sequencing (scTCR-seq) datasets from 21 recipient-donor pairs (42 samples in total) who achieved long-term immune homeostasis after allo-HSCT. The study cohort encompassed malignant diseases (AML/MDS; n=14 pairs) and non-malignant diseases (severe aplastic anemia, SAA; n=7 pairs), and included both HLA-matched sibling donor transplantation (MSDT) and HLA-haploidentical transplantation (haplo-SCT).

Global immune landscape analysis revealed that the underlying disease context profoundly shaped immune cell redistribution. Recipients with malignant diseases exhibited extensive immune-cell redistribution and transcriptional reprogramming compared to their paired donors. Conversely, recipients with non-malignant diseases largely preserved a donor-like immune composition. Despite these divergent immune reconstitution trajectories, we identified highly conserved cellular signatures. Specifically, CD8 regulatory precursor (CD8 Trp) cells and ZNF683hi CD8 effector T cells were consistently enriched in recipients relative to their donors across multiple clinical strata, including disease background, transplantation modality, donor and recipient age, graft source, CD34+ cell dose, donor-recipient sex, and post-transplant interval. Consistent with this enrichment, effector T-cell populations, including CD4 Teff, CD8 Tem, ZNF683hi CD8 Teff, and CD8 Trp cells, displayed increased functional activity in recipients, whereas naïve and memory T-cell subsets and CD4 Treg cells exhibited reduced functional scores compared with their paired donors. Furthermore, a strong correlation between ZNF683hi CD8 effector T cells and the expression of cytotoxic molecules was also revealed.

Leveraging TCR sequences as endogenous lineage tracers, we identified T cells harboring donor-recipient shared TCR clonotypes as graft-derived populations that persisted after transplantation. Transcriptomic profiling of identical shared clonotypes across donor and recipient microenvironments revealed recipient-specific upregulation of pathways associated with TCR signaling and T-cell activation. To investigate the intrinsic properties underlying the long-term persistence of these shared clonotypes, we compared their transcriptional profiles with those of donor-unique clonotypes in donor samples. Persistent clonotypes exhibited intrinsically higher TCR signaling activity and stronger effector program. Furthermore, a substantial fraction of persistent donor-recipient shared clonotypes were virus-reactive, particularly those recognizing cytomegalovirus (CMV). Following transplantation, these clones underwent selective expansion and acquired transcriptional programs associated with long-term survival, effector differentiation, and immune synapse organization.

These findings establish a single-cell resolution framework for immune homeostasis remodeling after allo-HSCT. We demonstrate that despite divergent global reconstitution patterns between malignant and non-malignant settings, successful long-term immune homeostasis converges on conserved cellular signatures and the selective retention, massive expansion, and functional adaptation of pre-existing donor cytotoxic effector T-cell clones.

Jianing Tang: No relevant conflicts of interest to declare.